VEGFB and Hepatic steatosis: A novel vascular endothelial growth factor B antibody (anti-VEGFB)/IL-22 fusion protein reduced renal and hepatic lipid accumulation and insulin resistance by downregulating fatty acid transporting gene expression and regulating glycolipid metabolism and ameliorated inflammatory responses by relieving oxidative stress and mitochondrial dysfunction, thus protecting db/m and HFD-fed db/db mice from diabetic nephropathy and liver steatosis [101].